These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25348496)

  • 1. Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan.
    Aoki T; Kokudo N; Komoto I; Takaori K; Kimura W; Sano K; Takamoto T; Hashimoto T; Okusaka T; Morizane C; Ito T; Imamura M
    J Gastroenterol; 2015 Jul; 50(7):769-75. PubMed ID: 25348496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
    Shibuya H; Hijioka S; Sakamoto Y; Ito T; Ueda K; Komoto I; Kobayashi N; Kudo A; Yasuda H; Miyake H; Arita J; Kiritani S; Ikeda M; Imaoka H; Ueno M; Kobayashi S; Furuta M; Nagashio Y; Murohisa G; Aoki T; Matsumoto S; Motoya M; Azemoto N; Itakura J; Horiguchi S; Yogi T; Kawagoe T; Miyaoka Y; Imamura F; Senju M; Arioka H; Hara K; Imamura M; Okusaka T
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):661-668. PubMed ID: 30054710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
    Ono H; Kudo A; Akahoshi K; Ogura T; Ogawa K; Ban D; Tanaka S; Tanabe M
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):793-799. PubMed ID: 31844980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
    Clewemar Antonodimitrakis P; Sundin A; Wassberg C; Granberg D; Skogseid B; Eriksson B
    Neuroendocrinology; 2016; 103(3-4):345-53. PubMed ID: 26279284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
    Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
    Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series.
    Müller C; Kreissl MC; Klose S; Krause A; Keitel V; Venerito M
    Medicine (Baltimore); 2022 Jan; 101(4):e28610. PubMed ID: 35089197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.
    Komoto I; Kokudo N; Aoki T; Morizane C; Ito T; Hashimoto T; Kimura W; Inoue N; Hasegawa K; Kondo S; Ueno H; Igarashi H; Oono T; Makuuchi M; Takamoto T; Hirai I; Takeshita A; Imamura M
    Jpn J Clin Oncol; 2022 Jul; 52(7):716-724. PubMed ID: 35411926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of streptozocin-based chemotherapy for gastroenteropancreatic neuroendocrine tumors in Japanese clinical practice.
    Murakami M; Fujimori N; Takamatsu Y; Ito T; Matsumoto K; Kakehashi S; Ohno A; Teramatsu K; Ueda K; Ishigami K; Ogawa Y
    Jpn J Clin Oncol; 2024 Jun; 54(6):647-657. PubMed ID: 38422348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
    Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
    Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.
    Krug S; Boch M; Daniel H; Nimphius W; Müller D; Michl P; Rinke A; Gress TM
    PLoS One; 2015; 10(12):e0143822. PubMed ID: 26630134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
    Okusaka T; Ueno H; Morizane C; Kondo S; Sakamoto Y; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):628-33. PubMed ID: 25940377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streptozocin-based chemotherapy is not history in neuroendocrine tumours.
    Weatherstone K; Meyer T
    Target Oncol; 2012 Sep; 7(3):161-8. PubMed ID: 22899468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.
    Hijioka S; Sakuma K; Aoki M; Mizuno N; Kuwahara T; Okuno N; Hara K; Yatabe Y
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):43-52. PubMed ID: 30310970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy.
    Lahner H; Mathew A; Klocker AL; Unger N; Theysohn J; Rekowski J; Jöckel KH; Theurer S; Schmid KW; Herrmann K; Führer D
    Endocrine; 2022 Jan; 75(1):293-302. PubMed ID: 34480724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases.
    Cloyd JM; Omichi K; Mizuno T; Kawaguchi Y; Tzeng CD; Conrad C; Chun YS; Aloia TA; Katz MHG; Lee JE; Halperin D; Yao J; Vauthey JN; Dasari A
    Ann Surg Oncol; 2018 Jun; 25(6):1709-1715. PubMed ID: 29626307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
    Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
    World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
    Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
    Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
    Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
    JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.